Sugi Predict

Sugi Predict / Compounds / 4-Nitro-Cinnamanilide

4-Nitro-Cinnamanilide

4-Nitro-Cinnamanilide

SCHEMBL3021597

O=C(C=Cc1ccc([N+](=O)[O-])cc1)Nc1ccccc1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.72
▸ RAB9A P51151 7/20 0.72
▸ NPC1 O15118 6/20 0.72
▸ SMN1; SMN2 Q16637 6/20 0.72
▸ ALDH1A1 P00352 4/20 0.72
▸ POLB P06746 1/20 0.72
▸ MMP1 P03956 2/20 0.69
▸ MMP2 P08253 2/20 0.69
▸ MMP9 P14780 2/20 0.69
▸ MAOB P27338 2/20 0.69
▸ EGFR P00533 1/20 0.69
▸ MAOA P21397 1/20 0.69
▸ KMT2A Q03164 10/20 0.67
▸ TDP1 Q9NUW8 1/20 0.67
▸ MEN1 O00255 9/20 0.66
▸ MAPK1 P28482 3/20 0.66
▸ LMNA P02545 3/20 0.62
▸ BCHE P06276 1/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.62
▸ KDM4E B2RXH2 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021602 0.94 MMP1 (0.69) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL15306486 0.94 MMP1 (0.69) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
4-Nitro-(4'-Nitro)Cinnamanilide SCHEMBL5315660 0.92 KMT2A (0.70) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL6097501 0.86 KMT2A (0.72) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL8063757 0.86 KMT2A (0.77) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL8063754 0.86 KMT2A (0.77) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL23547197 0.85 TRPV1 (0.73) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL6754378 0.85 TRPV1 (0.73) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL6754380 0.85 TRPV1 (0.73) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL20526855 0.84 KMT2A (0.73) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9162991-B2 Cinnamoyl inhibitors of transglutaminase UNIVERSITY OF OTTAWA (CA) 2015-10-20 — — US disclosed
US-20140024837-A1 CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE UNIVERSITE DE MONTREAL (CA) 2014-01-23 — — US disclosed
US-8614233-B2 Cinnamoyl inhibitors of transglutaminase UNIVERSITE DE MONTREAL (CA) 2013-12-24 — — US disclosed
US-20100204280-A1 CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE UNIVERSITE DE MONTREAL (CA) 2010-08-12 — — US disclosed
CN-1314660-C Cinnamide compound synthesizing process UNIV ZHEJIANG (CN) 2007-05-09 — — CN disclosed
CN-1740145-A Cinnamide compound synthesizing process UNIV ZHEJIANG (CN) 2006-03-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204280-A1 CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE TGM2, TGM3, TGM1 MAPT 1920/4885RAB9A 2132/4885NPC1 2429/4885
US-20140024837-A1 CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE TGM2, TGM3, TFPI MAPT 2474/4885RAB9A 2229/4885NPC1 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.